Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126946 | 0.93 | KCNQ3 (0.35) | SMN1; SMN2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL4135601 | 0.93 | SMN1; SMN2 (0.34) | SMN1; SMN2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL4127374 | 0.93 | SCN9A (0.37) | SMN1; SMN2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL2838664 | 0.91 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1RAB9ARIPK1P2RX7 | |
| SCHEMBL4125531 | 0.90 | CNR1 (0.40) | KCNQ3KCNQ2P2RX7 | |
| SCHEMBL4131694 | 0.90 | KCNQ3 (0.36) | SMN1; SMN2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL4125753 | 0.89 | CNR1 (0.34) | SMN1; SMN2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL4130354 | 0.89 | RXRA (0.32) | SMN1; SMN2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL4123630 | 0.89 | MDM2 (0.38) | SMN1; SMN2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL4118494 | 0.88 | SMN1; SMN2 (0.33) | SMN1; SMN2NPC1RAB9AKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SMN1; SMN2 4327/4885NPC1 53/4885RAB9A 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.